The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Phase 3 Studies Evaluate Lesinurad for Gout Treatment

Phase 3 Studies Evaluate Lesinurad for Gout Treatment

July 15, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Baseline sUA measurement was 6.90 ± 1.19 mg/dL, with 23.6% having tophi. Both lesinurad-treated groups had significantly increased proportions of patients achieving sUA targets compared with placebo plus allopurinol-treated patients. Approximately twice as many patients achieved these targets at Month 6. At Month 6, sUA < 6 mg/dL, lesinurad 200 mg results were 54%, lesinurad 400 mg results were 59% and placebo results were 23%. There were no significant differences observed between groups in mean rate of GFRT or with complete target tophus resolution. Safety was similar to CLEAR 1. Lesinurad combined with allopurinol was well tolerated and met study endpoints without severe toxicity.

You Might Also Like
  • FDA Approves Lesinurad + Allopurinol
  • Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
Also By This Author
  • Drug Updates: EULAR 2012

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Saag K, Fitz-Patrick D, Kopicko J, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: Results from a phase 3 study in gout patients having an inadequate response to standard of care (CLEAR 1). Ann Rheum Dis. 2015 June; 74(Suppl2):540. Abstract FRI0320. doi: 10.1136/annrheumdis-2015-EULAR.3273
  2. Bardin T, Keenan R, Khanna P, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: Results from a phase 3 study in gout patients having an inadequate response to standard of care (CLEAR 2). Ann Rheum Dis. 2015 June; 74(Suppl2):545. Abstract FRI0333. doi: 10.1136/annrheumdis-2015-EULAR.1238

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis, Drug Updates Tagged With: Allopurinol, EULAR, Gout, lesinurad

You Might Also Like:
  • FDA Approves Lesinurad + Allopurinol
  • Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
  • The ACR’s & EULAR’s Gout Guidelines Include Treatment Approaches

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)